Susan Elizabeth Dorman, M. D.

Curriculum Vitae

Name: Susan E. Dorman

Date: November 18, 2003

DEMOGRAPHIC INFORMATION

Current Appointment:

Assistant Professor of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine

Personal Data:

Johns Hopkins Center for Tuberculosis Research

1503 East Jefferson Street, Room 105

Baltimore, Maryland 21231

Phone: 410-502-2717

Fax: 410-955-0740

Email:

Education and Training:

B. S. 1987 Trinity College, Hartford, Connecticut (Biochemistry)

M.D. 1993 Duke University School of Medicine (Medicine)

1993-1994 Internship in Internal Medicine

Brigham and Women’s Hospital, Boston, Massachusetts

1994-1996 Residency in Internal Medicine

Brigham and Women’s Hospital, Boston, Massachusetts

1996-1999 Fellowship in Infectious Diseases

National Institutes of Health, Bethesda, Maryland

Professional Experience:

1991-1992 Howard Hughes Medical Institute-National Institutes of Health Research Scholar, Laboratory of Host Defenses, NIAID

National Institutes of Health, Bethesda, Maryland

1999-2000 Clinical Associate, Immunopathogenesis Unit, Laboratory of Host Defenses, National Institutes of Health, Bethesda, Maryland

2000-2001 Clinical Associate, Tuberculosis Research Unit, Laboratory of Host Defenses, National Institutes of Health, Bethesda, Maryland

2001-present Assistant Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

2003-present Medical Director (Interim), Baltimore City Eastern Chest Clinic

RESEARCH ACTIVITIES

Publications

1. Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Newport M, Levin M, Roesler J, Rosenzweig S, Kumararatne D, Casanova JL, Holland SM. Clinical features of dominant and recessive IFNg receptor 1 deficiencies. (manuscript submitted).

2. Conde MB, Suffys P, Lapa e Silva Jose Roberto, Kritski AL, Dorman SE. IgA and IgG immune responses against P-90 antigen for the diagnosis of pulmonary tuberculosis and screening for Mycobacterium tuberculosis infection. Clinical and Diagnostic Laboratory Immunology 2004 (in press).

3. Karakousis PC, Bishai WR, Dorman SE. Mycobacterium tuberculosis cell envelope lipids and the host immune response. Cellular Microbiology 2004 (in press).

4. Dorman SE, Hatem CL, Tyagi S, Aird K, Lopez-Molina J, Pitt MLM, Zook BC, Dannenberg AM Jr, Bishai WR, Manabe YC. Susceptibility to tuberculosis: clues from studies with inbred and outbred New Zealand white rabbits. Infect Immun 2004 (in press).

5. Dowdy DW, Maters A, Parrish N, Beyrer C, Dorman SE. Cost-effectiveness analysis of the Gen-Probe amplified Mycobacterium tuberculosis direct test as used routinely on smear-positive respiratory specimens. J Clin Micriobiol 2003;41:948-53.

6. Park WG, Bishai WR, Chaisson RE, Dorman SE. Performance of the microscopic observation drug susceptibility (MODS) assay for Mycobacterium tuberculosis drug susceptibility testing. J Clin Microbiol 2002;40:4750-2.

7. Gounder C, Carvalho de Queiroz Mello, F, Conde M, Bishai WR, Kritski A, Chaisson RE, Dorman, SE. Field evaluation of a rapid immunochromatographic test for tuberculosis. J Clin Microbiol 2002;40:1989-93.

8. Conville PS, Lee JW, Anderson VL, Dorman SE, Holland SM, Sneller MC, Cahill B, Carroll KC, Witebsky FG. Nocardia africana/veterana as a pathogen in North American patients. (in press)

9. Dorman SE, Guide SV, Conville PS, DeCarlo ES, Malech HL, Gallin JI, Witebsky FG, Holland SM. Nocardia infections in chronic granulomatous disease. Clin Infect Dis 2002 35:390-4.

10. Rosenzweig S, Dorman SE, Roesler J, Palacios J, Zelazko M, Holland SM. 561del4 defines a novel small deletion hotspot in the interferon gamma receptor 1 chain. Clin Immunol 2002;102:25-7.

11. Sterling TR*, Dorman SE*, Chaisson RE, Hackman J, Moore K, Holland SM. Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis 2001;33:976-982 (* authors contributed equally).

12. Dorman SE, Cannon ME, Telford SR 3rd, Frank KM, Churchill WH. Fulminant babesiosis treated with clindamycin, quinine, and whole-blood exchange transfusion. Transfusion 2000;40:375-80.

13. Jouanguy E, Lamhemedi-Cherradi S, Lammas D, Dorman SE, Fondaneche MC, Dupuis S, Doffinger R, Altare F, Girdlestone J, Emile JF, Ducoulombier H, Edgar D, Clarke J, Oxellus VA, Brai M, Novelli V, Heyne K, Fischer A, Holland SM, Kumararatne DS, Schreiber RD, Casanova JL. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nature Genet 1999;21:370-378.

14. Fleisher TA, Dorman SE, Anderson JA, Vail M, Brown MR, Holland SM. Detection of intracellular phosphorylated STAT-1 by flow cytometry. Clin Immunol 1999;90:425-430.

15. Lekstrom-Himes J, Dorman SE, Kopar P, Holland SM, Gallin JI. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAT/enhancer binding protein epsilon. J Exp Med 1999;189:1847-1852.

16. Dorman SE, Uzel G, Roesler J, Bradley JS, Bastian J, Billman G, King S, Filie A, Schermerhorn J, Holland SM. Viral infections in interferon-g receptor deficiency. J Peds 1999;135:640-643.

17. Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, Noel GJ, Vesterhus P, Brown MR, Fleisher TA. Abnormal regulation of interferon-g, interleukin-12, and tumor necrosis factor-a in human interferon-g receptor deficiency. J Infect Dis 1998;178:1095-1104.

18. Dorman SE, Holland SM. Mutation in the signal transducing chain of the interferon gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998;101:2364-2369.

19. Dorman SE, Heller HM, Basgoz NO, Sax PE. Adjunctive corticosteroid therapy for patients whose treatment for disseminated Mycobacterium avium complex infection has failed. Clin Infect Dis 1998;26:682-686.

20. Dorman SE, Gill VJ, Gallin JI, Holland SM. Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease, and review of occurrences in the Americas. Clin Infect Dis 1998;26:889-894.

EXTRAMURAL SCHOLARSHIP

Current

Rapid detection of Mycobacterium PI: Dorman, S 12/1/02-11/30/07

tuberculosis infection 75%

NIAID 1 K23 AI051528-01A1

Total Direct Costs: $608,750

Extracellular matrix TGFB- PI: Dorman, S 7/1/02-6/30/04

binding proteins in pulmonary TB 5%

American Lung Association of Maryland

Total Direct Costs: $70,000

Mycobacterium tuberculosis PI: Dorman SE 12/1/03-11/30/05

Cell wall virulence factors NIAID/NIH 1 RO3 AI054491-01

Total Direct Costs: $100,000

Gorgas Tuberculosis Initiative PI: Chaisson, RE 9/30/98-1/31/04

10%

United States Agency for International Development

Total Direct Costs: $828,000

TB Trial Consortium PI: Sterling, TR 10/1/99-9/30/09

5%

Centers for Disease Control

Total Direct Costs: $2,121,562

An Alternative Proposal for PI: Chaisson, RE 10/1/02-9/30/09

TBTC Expansion 5%

Centers for Disease Control

Total Direct Costs: $2,417,621

EDUCATIONAL ACTIVITIES

Mentoring Advisees:

Walter Park, B.S., 2001-2002, medical student at Johns Hopkins School of Medicine

David Dowdy, B.A., 2001-2002, Masters degree candidate in Epidemiology, Johns Hopkins University Bloomberg School of Public Health

Teaching Activities

2002, 2003 “Tuberculosis: Host Susceptibility and Immune Responses” lecture for Johns Hopkins Bloomberg School of Public Health Winter Institute short course “Major Global Infectious Diseaseses: Prospects for Control”

2002, 2003 “Mycobacterial Infections” lecture at Johns Hopkins Internal Medicine Review Course

2003 Immunology of Tuberculosis” lecture for Johns Hopkins Bloomberg School of Public Health, Graduate Immunology: The Immune Response (260.717)

2003 “Tuberculosis: Clinical Disease and Diagnosis” lecture for Johns Hopkins Bloomberg School of Public Health Summer Course on Tropical Medicine

2003 Preceptor, Johns Hopkins School of Medicine “Clinical Skills” Course for Medical Students

Editorial Activities:

Ad hoc reviewer for:

Clinical Infectious Diseases

Journal of Infectious Diseases

Journal of Biological Chemistry

International Journal of Tuberculosis and Lung Disease

Trends in Microbiology

Journal of Clinical Microbiology

CLINICAL ACTIVITIES

Certification:

1996 Maryland medical license #D0050507

1996 Diplomate, American Board of Internal Medicine #167323

1998 Diplomate, Subspecialty Board of Infectious Diseases #167323

Service Responsibilities:

JHH Inpatient AIDS Service Attending, 2 weeks/yr, 2001-present

JHH Infectious Diseases Consult Attending, 2 weeks/yr, 2001-present

Baltimore City Eastern Chest Clinic, 10% time, 2001-present

Medical Director, Baltimore City Eastern Chest Clinic, 2003-present

ORGANIZATIONAL ACTIVITIES

Reviewer for:

2002 US Department of Health and Human Services Biotechnology Engagement Program grants

2002, 2003 World Health Organization “Bright Ideas” Program for Novel TB Diagnostic Methods

RECOGNITION

Awards and Honors:

1984 Trinity College Faculty Scholar Prize

1986 Phi Beta Kappa

1986 Trinity College President’s Fellow in Biochemistry

1987 American Institute of Chemists Student Award

1987 Louis Aronne Prize in Biochemistry, Trinity College

1992 United States Public Health Service Senior Commissioned Officer Student Training and Extern Program (COSTEP) Award

1992 Howard Hughes Medical Institute Research Training Fellowship

1993 Alpha Omega Alpha

1993 E.E. Owen Clinical Scholar Award

1998 Travel Award, Immunocompromised Host Society

1998 Henry Christian Award, American Federation for Medical Research

Invited Talks:

2003 Expert Panel member: Maryland Tuberculosis, Refugee, and Migrant Health Program Annual Meeting

2003 Immunology of Tuberculosis. II Simposio de Atualizacao em Tuberculose, April 14-15, Rio de Janeiro, Brazil.

2002 Immunology of Tuberculosis: Clinical Implications. I Simposio de Atualizacao em Tuberculose, March 25-26, Rio de Janeiro, Brazil.

2000 IFNg Receptor Deficiency: a Window to Understanding Human Host Defense against Mycobacterial Infections. 100th Annual Meeting of the American Society for Microbiology. May 21-25, 2000, Los Angeles, CA.

Invited Review:

Dorman SE, Holland SM. Interferon-g and interleukin-12 pathway defects and human disease. Cytokine and Growth Factor Rev 2000;11:321-333.